Questcor (QCOR +3.5%) moves higher on positive comments out of its conference call this morning...


Questcor (QCOR +3.5%) moves higher on positive comments out of its conference call this morning to discuss the commercialization of its rheumatology drug, Acthar. Oppenheimer says its highly encouraged by the not only the drugs prospects, but also the company's ability to execute its strategy, while both Caris and Jefferies say Street estimates don't factor in the drug effectively, and will have to move higher.

From other sites
Comments (1)
  • Ernest P Icahn
    , contributor
    Comments (364) | Send Message
     
    Particularly peculiar that an Oppenheimer Fund has a substantial stake in QCOR, ain't it?
    17 Jun 2012, 08:50 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs